Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Royalty Pharma (Nasdaq: RPRX) reported strong financial results for Q2 2024, showcasing a 12% growth in Portfolio Receipts to $608 million and 11% growth in Royalty Receipts to $605 million. The company raised its 2024 full-year guidance for Portfolio Receipts to $2,700-$2,775 million. Highlighting their capital deployment of over $2 billion, investments spanned six therapies, including notable partnerships with Cytokinetics, PTC Therapeutics, and Agios. Significant clinical updates featured positive Phase 3 results for Tremfya and FDA approval of Voranigo. Additionally, Royalty Pharma repurchased Class A ordinary shares worth $115 million YTD and maintained robust liquidity with $1.8 billion in cash and $7.8 billion in debt.
Royalty Pharma (Nasdaq: RPRX) has appointed Molly Sawaya as Executive Vice President, Head of Human Capital. Sawaya joins from Hudson Bay Capital, where she was Managing Director and Head of Colleague Experience. She brings nearly 15 years of HR experience from global organizations, including QBE Insurance Group, Perpetual , and National Australia Bank.
Sawaya holds a Bachelor of Arts and Master of Applied Science in Psychology from the University of Sydney. CEO Pablo Legorreta emphasized her role in fostering a thriving work environment and supporting the company's growth as it continues to scale. This appointment aims to strengthen Royalty Pharma's leadership team and cultivate its unique culture.
Royalty Pharma plc (Nasdaq: RPRX) has announced that it will release its second quarter 2024 financial results on Thursday, August 8, 2024, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time on the same day to discuss the results.
Investors can access the conference call information and view the live webcast on the 'Investors' page of Royalty Pharma's website. A replay of the conference call and webcast will be available on the company's website for at least 30 days after the event.
Royalty Pharma plc (Nasdaq: RPRX) has announced its dividend for the third quarter of 2024. The company's board of directors has approved a payment of $0.21 per Class A ordinary share. This dividend will be distributed on September 13, 2024, to shareholders who are on record as of the close of business on August 16, 2024. This announcement provides investors with information about the company's ongoing commitment to returning value to shareholders through regular dividend payments.
Royalty Pharma (Nasdaq: RPRX) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. The company will engage in a fireside chat scheduled for 2:00 p.m. ET. The event will be webcast live and later archived for at least thirty days, accessible through Royalty Pharma's Events page.
Royalty Pharma (Nasdaq: RPRX) announced the pricing of $1.5 billion in senior unsecured notes.
The offering includes $500 million of 5.150% Notes due 2029, $500 million of 5.400% Notes due 2034, and $500 million of 5.900% Notes due 2054. These notes will be guaranteed by Royalty Pharma Holdings.
The transaction is expected to close on June 10, 2024. Proceeds will be used for general corporate purposes.
Major financial institutions such as BofA Securities, Citigroup, and J.P. Morgan are among the joint lead book-running managers.
Royalty Pharma announced a $905 million agreement with Agios Pharmaceuticals to acquire future royalties on Servier’s vorasidenib, contingent on FDA approval. Vorasidenib, a targeted therapy for IDH-mutant glioma, has shown unprecedented efficacy and tolerability in Phase 3 trials and received priority review with a PDUFA date of August 20, 2024.
The drug is projected to achieve over $1 billion in annual peak sales in the U.S., potentially generating more than $150 million in annual royalties for Royalty Pharma. If approved, royalties may continue through 2038.
An investor call is scheduled for today, May 28, to discuss the deal.
Royalty Pharma and Cytokinetics announced an expanded strategic funding collaboration worth up to $575 million to support the commercialization of aficamten and advance Cytokinetics' cardiovascular R&D pipeline. The deal includes immediate $250 million funding and additional funding options tied to clinical and regulatory milestones. Key elements are commercial launch funding, royalty restructuring, development funding for clinical trials, and equity purchase by Royalty Pharma. This collaboration aims to fortify Cytokinetics' capital structure and help the company achieve its strategic goals in cardiology.
Royalty Pharma plc (Nasdaq: RPRX) will be presenting at upcoming investor conferences, including the RBC Capital Markets 2024 Global Healthcare Conference and BofA Securities 2024 Healthcare Conference in May. The webcasts will be available on Royalty Pharma's website for at least thirty days.
Royalty Pharma plc (Nasdaq: RPRX) reported 14% growth in Royalty Receipts driving Portfolio Receipts of $717 million for the first quarter of 2024. Full year 2024 guidance confirmed at $2,600 to $2,700 million with a commitment to grow dividends annually. The company's development-stage portfolio has expanded significantly, with key events expected in the coming year. Financial capacity of over $3.5 billion to execute transactions, despite a decline in Portfolio Receipts due to a high base of comparison. Strong Royalty Receipts growth and a focus on new royalty opportunities demonstrate a robust business strategy.